{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"226","upperLimit":"505","value":"309"},{"comment":"only one subject with PR","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented). CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum.","dispersionType":"Full Range","groups":[{"description":"Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle","id":"OG000","title":"Sorafenib (Nexavar, BAY43-9006)"},{"description":"Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"FAS - responders only","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years","title":"Duration of Response (DOR) Based on Central Assessment","type":"SECONDARY","unitOfMeasure":"Days"}